Cell Therapeutics, Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer

Sept. 24, 2007 - Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) has begun a confirmatory phase III clinical trial of combination chemotherapy for women with advanced non-small cell lung cancer (NSCLC) -- the most lethal cancer facing women today. The trial, known as PGT307, will focus exclusively on women with pre-menopausal estrogen levels -- a group whose survival is significantly shorter than post-menopausal women. XYOTAX (TM) (paclitaxel poliglumex) will be studied in combination with carboplatin versus paclitaxel/carboplatin in female NSCLC patients with performance status of 0, 1, or 2... Cell Therapeutics' Press Release -